This week, Eli Lilly and Company announced additional findings indicating that its rheumatoid arthritis drug, baricitinib, may improve the health of severe Covid-19 patients when used in combination with Gilead Science’s antiviral drug remdesivir.
Outcomes of the study, which the company had reported preliminary data from in September, suggest that the two drugs in combination reduce hospitalization stays by one day compared to the use of remdesivir alone. The data also indicates that the drug combination increases chances of severe Covid-19 patients surviving by about 35%. That increase was more pronounced in those patients who required supplemental oxygen.
“We’re obviously extraordinarily pleased that it has an impact on the mortality rate,” says Ilya Yuffa, president of Lilly Biosciences.
The findings come from a large study called the Adaptive Covid-19 Treatment Trial (ACTT-2), which is sponsored by the National Institutes of Health. The full data and study writeup will be